Abstract Details

Title Categorical change in T2 lesion volume and clinical outcomes in the phase III FREEDOMS and its extension study, evaluating fingolimod in patients with relapsing-remitting multiple sclerosis

Topic Multiple Sclerosis

Presentation(s) (-)

Poster/Presentation
Number 166

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Douglas R. Jeffery, MD, PhD (Lake Norman Neurology At Piedmont Health Care) PRESENTER	No disclosure on file
Claire E. Carrazco, DO (Emerson Hospital)	No disclosure on file
Elisabetta Verdun Di Cantogno, MD (Merck Serono Int, SA)	Dr. Verdun Di Cantogno has received personal compensation for serving as an employee of EMD Serono Research & Development Institute, Inc., Billerica, MA, USA. Dr. Verdun Di Cantogno has stock in EMD Serono Research & Development Institute, Inc., Billerica, MA, USA.
	No disclosure on file
	No disclosure on file
Peter S. Chin, MD (Denali)	No disclosure on file
William Camu, MD (Centre Gui de Chauliac)	No disclosure on file

�鶹��ýӳ��

�鶹��ýӳ��

Abstract Details